Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
William T. McClintic ; Zachary D. Chandler ; Lalitha M. Karchalla , et al. J. Pharmacol. Exp. Ther.,2024,388(2):637-646. DOI: 10.1124/jpet.123.001773
More
Abstract: Botulinum neurotoxin (BoNT) is a potent protein toxin that causes muscle paralysis and death by asphyxiation. Treatments for symptomatic botulism are intubation and supportive care until respiratory function recovers. Aminopyridines have recently emerged as potential treatments for botulism. The clinically approved drug 3,4-diaminopyridine (3,4-DAP) rapidly reverses toxic signs of botulism and has antidotal effects when continuously administered in rodent models of lethal botulism. Although the therapeutic effects of 3,4-DAP likely result from the reversal of diaphragm paralysis, the corresponding effects on respiratory physiology are not understood. Here, we combined unrestrained whole-body plethysmography (UWBP) with arterial blood gas measurements to study the effects of 3,4-DAP, and other aminopyridines, on ventilation and respiration at terminal stages of botulism in mice. Treatment with clinically relevant doses of 3,4-DAP restored ventilation in a dose-dependent manner, producing significant improvements in ventilatory parameters within 10 minutes. Concomitant with improved ventilation, 3,4-DAP treatment reversed botulism-induced respiratory acidosis, restoring blood levels of CO2, pH, and lactate to normal physiologic levels. Having established that 3,4-DAP–mediated improvements in ventilation were directly correlated with improved respiration, we used UWBP to quantitatively evaluate nine additional aminopyridines in BoNT/A-intoxicated mice. Multiple aminopyridines were identified with comparable or enhanced therapeutic efficacies compared with 3,4-DAP, including aminopyridines that selectively improved tidal volume versus respiratory rate and vice versa. In addition to contributing to a growing body of evidence supporting the use of aminopyridines to treat clinical botulism, these data lay the groundwork for the development of aminopyridine derivatives with improved pharmacological properties.
Purchased from AmBeed: 18614-51-2 ; 159783-22-9 ; 1990-90-5 ; 618439-82-0
CAS No. : | 1990-90-5 | MDL No. : | MFCD01704431 |
Formula : | C6H8N2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | VGJLGPCXUGIXRQ-UHFFFAOYSA-N |
M.W : | 108.14 | Pubchem ID : | 74811 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | With palladium 10% on activated carbon; hydrogen In ethanol at 16 - 30℃; for 36 h; | Step 2: A solution of 3-methyl-4-nitropyridine /V-oxide (30.0g, 195 mmol) and 10percent Pd-C (6.0 g) in EtOH (450 mL) was stirred at rt under H2 (5 bar) for 36 h. The RM was filtered through a pad of celite™ and the volatiles were removed under reduced pressure to yield the desired compound (20.0 g, 95percent). |
83.6% | With hydrogen In water; acetic acid for 2.5 h; | 3-Methyl-4-nitropyridine 1-oxide (5.85 g) was dissolved in glacial acetic acid (115 mL) and hydrogenated in a Parr hydrogenation apparatus (catalyst: 220 mg Pt02 x 2 H20, 50 psi) at ambient temperature for 2.5 h. Then the catalyst was filtered off and the solvent was evaporated. After addition of 150 mL of water the pH was adjusted to 12 by addition of 2N NaOH. The resulting solution was extracted 10 times with 100 mL of dichloromethane (containing 5 percent methanol). The combined organic phases were dried over anhydrous sodium sulphate and evaporated to give 3.81 g (83.6percent) of 4-amino-3-methylpyridine. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
31.3% | at 20 - 60℃; for 15 h; | 4-Amino-3-methylpyridine (3.00 g) was dissolved with icecooling in concentrated sulfuric acid (36 mL). Then, fuming nitric acid (4,72 g) was added dropwise. After stirring at room temperature for 1 h, the solution was heated at 60 C for 14 hours. After cooling to ambient temperature, the reaction mixture was poured on ice and the resulting solution was adjusted to pH 13 by addition of solid KOH. The precipitate was filtered off, washed with water and dried. Yield: 1. 198 g (31. 3percent) 4-amino-3- methyl-5-nitropyridine. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
78% | With hydrogen bromide; dihydrogen peroxide In water at 70℃; for 2 h; | Example 36 7- (2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo [4,3-c] pyridine NH2 Me step 1 Br, 97 97 98 99 Me v step step 1 ) ci ci ci C1 100 101 102 NH2 NAC2STEP 1 To a solution of 4-amino-3-picoline (97,10 g, 0.092 mmol) and HBr (50 mL) heated to 70° C was added 15percent H202 (16 mL) over a 1 h period. The reaction mixture was stirred for additional h and poured in ice (100 g). The pH of the solution was adjusted to about 5 with 50percent NAOH and the resulting red precipitate was filtered. The pH was raised to about 9 and the resulting white precipitate was collected by filtration to afford 98 (13.5 g, 78percent theory) |